Physician profile
Morgan Simpson
NPI 1548707409
$1,747.21
in general payments reported to CMS, 2019-2025
19 companies · $888 in 2025
The $888 reported for 2025 was more than what 85% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.00 · 2022: $105 · 2023: $162 · 2024: $580 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,629.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $342.06 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $339.33 | 2023-2025 | |
| Novo Nordisk INC | $278.06 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $169.08 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $139.48 | 2022-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $89.36 | 2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $82.37 | 2024-2025 | Voquezna |
| Pfizer INC. | $60.61 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.35 | 2024-2025 | Jardiance |
| Seqirus USA INC | $29.24 | 2025 | Fluad, Flucelvax |
| Abbott Laboratories | $22.61 | 2024 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $20.77 | 2024 | Trintellix |
| Cranial Technologies, INC | $20.10 | 2025 | Doc Band |
| Axsome Therapeutics, INC. | $19.24 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $18.53 | 2023 | Rexulti |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $16.32 | 2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $15.96 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.74 | 2024 | Xifaxan |
| Avanir Pharmaceuticals, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.